Join the Psoriasis group to help and get support from people like you.
Psoriasis News (Page 2)
Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis
Coronary Microvascular Dysfunction ID'd in 31.5 Percent With Psoriasis
WEDNESDAY, Sept. 20, 2023 – Coronary microvascular dysfunction (CMD) occurs in 31.5 percent of patients with psoriasis, with disease severity and duration associated with increased risk, according...
Is It Eczema or Psoriasis? An Expert Offers Advice
FRIDAY, Sept. 8, 2023 – Eczema and psoriasis are skin conditions that can each affect a person’s quality of life. The best way to know which one you have if you have an itchy rash or burning feeling ...
Model Predicts New Psoriatic Arthritis in People With Psoriasis
FRIDAY, Aug. 11, 2023 – The development of psoriatic arthritis (PsA) can be predicted with reasonable accuracy for psoriasis patients, according to a study published online Aug. 9 in Arthritis &...
Co-Occurrence of Psoriasis and Rheumatic Diseases Common
FRIDAY, Aug. 11, 2023 – Psoriasis is associated with rheumatic diseases, according to a study published online Aug. 5 in the Journal of the American Academy of Dermatology. Mimi Chung, from the...
Low Vitamin D Levels Tied to Higher Severity of Psoriasis
FRIDAY, July 28, 2023 – Lower vitamin D levels and a higher proportion of vitamin D deficiency are associated with increasing psoriasis severity, according to a study presented during NUTRITION...
Vitamin D Might Ease the Agony of Psoriasis
TUESDAY, July 25, 2023 – People who have psoriasis may want to get their vitamin D levels checked. New research suggests that blood levels of the so-called "sunshine vitamin" may affect the severity...
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral t...
FDA Approves Spevigo (spesolimab-sbzo) for Generalized Pustular Psoriasis (GPP) Flares in Adults
More than half of patients treated with Spevigo (spesolimab-sbzo) injection, for intravenous use showed no visible pustules one week after receiving treatment Spesolimab is a monoclonal antibody...
FDA Approves Zoryve (roflumilast) Cream for the Treatment of Plaque Psoriasis
WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful i...
FDA Approves Vtama (tapinarof) Cream for the Treatment of Plaque Psoriasis in Adults
LONG BEACH, Calif., and BASEL, Switzerland, May 24, 2022 — Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, t...
FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level
THOUSAND OAKS, Calif., Dec. 20, 2021 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult ...
Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis
EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ – Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx...
FDA Approves Wynzora Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis
COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / – MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions,...
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
INDIANAPOLIS, March 30, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application...
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Plaque Psoriasis, Dermatological Disorders
Related drug support groups
prednisone, methylprednisolone, methotrexate, Humira, triamcinolone, clobetasol, fluocinonide, Remicade, prednisolone, view more... Stelara, Cosentyx, Skyrizi, adalimumab, etanercept, dexamethasone, desonide, halobetasol, Taltz